PubMed · 15019355
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
Eric L Singman. 2004. Preferred practice pattern changes.. https://doi.org/10.1016/j.ophtha.2003.12.038
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Explore the source record for details and available documents.
BACKGROUND: DB289 is the orally active prodrug of the diamidine DB75, which was developed for the treatment of human African trypanosomiasis. METHODS: We tested the safety and efficacy of DB289 for the treatment of Plasmodium vivax and acute, uncomplicated P. falciparum infections in an open-label pilot study at the Hospital for Tropical Diseases in Bangkok. Nine patients with P. vivax infections and 23 patients with P. falciparum infections were admitted and treated with 100 mg of DB289 given orally twice a day for 5 days and were followed for 28 days. Patients with P. vivax infections were also treated with primaquine on days 10-23. RESULTS: All patients cleared parasites by day 7, with a mean+/-SD clearance time of 43+/-41 h. One patient with a P. vivax infection had a recurrence of parasitemia on day 9. Of the 23 patients with P. falciparum infections, 3 had recurrences of parasitemia caused by P. vivax and 2 had recurrences of parasitemia caused by P. falciparum. In only 1 of 2 recurrences of parasitemia caused by P. falciparum were the parasites genotypically distinct from the infecting parasites the patient had at enrollment, which means there was a 96% cure rate. CONCLUSIONS: DB289 is a promising new antimalarial compound that could become an important component of new antimalarial combinations.
The authors report a case of mucocutaneous leishmaniasis in a 45-year-old patient who was unsuccessfully treated with pentavalent antimonial for 30 days. After 10 days from the initial treatment and before starting a new therapeutic regimen with the same drug the patient died due to sudden cardiac arrest.